Optimal Timing of Dupilumab Application in CRSwNP: Impact of “Neoadjuvant Therapy” on Surgical Outcomes at 1 Year
Preoperative neoadjuvant dupilumab (two doses) combined with full-house endoscopic sinus surgery (ESS) eliminates polyp recurrence at 12 months versus 50% recurrence in ESS-only cohort. Dupilumab-ESS cohort showed superior objective outcomes but comparable subjective symptom relief in this pilot study. "Neoadjuvant therapy" may reduce long-term biologic dependency and costs, while enabling sustained control with topical corticosteroids postoperatively.
Authors
- Meng Wu (ORCID: https://orcid.org/0000-0001-7381-5591)
- T.W. Kang
- Zhenzhen Zhu (ORCID: https://orcid.org/0000-0003-3245-3306)
- Weiqing Wang (ORCID: https://orcid.org/0000-0002-9440-1117)
- Wei Lv (ORCID: https://orcid.org/0000-0001-5311-0316)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1002/alr.70014
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality